Lycit-AM Tablet SR is a combination medication containing Montelukast 10 mg, Levocetirizine 5 mg, and Acebrophylline 200 mg, formulated for sustained release to provide prolonged therapeutic effects. Montelukast, a leukotriene receptor antagonist, plays a crucial role in managing asthma and allergic rhinitis by inhibiting leukotriene-mediated bronchoconstriction and inflammation. Levocetirizine, a third-generation non-sedating antihistamine, effectively alleviates symptoms of allergic conditions such as rhinitis and urticaria by selectively blocking peripheral H1 histamine receptors. Acebrophylline, a bronchodilator with mucolytic and anti-inflammatory properties, facilitates airway clearance and improves respiratory function in obstructive airway diseases like chronic bronchitis and asthma. The synergistic action of these agents makes Lycit-AM Tablet SR particularly beneficial for patients with coexisting allergic and obstructive airway disorders, providing relief from bronchospasm, airway inflammation, mucus hypersecretion, and allergic symptoms. The sustained-release formulation ensures steady plasma concentrations, enhancing compliance and minimizing dosing frequency. Lycit-AM Tablet SR should be used under medical supervision, considering contraindications such as hypersensitivity to any component, and caution is advised in patients with hepatic or renal impairment. Common adverse effects may include headache, gastrointestinal discomfort, and mild sedation. This combination therapy offers an effective approach to managing complex respiratory and allergic conditions.